Trial · NCT07484113
IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD
NCT07484113, Phase 1, Not yet recruiting, Stanford University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD. Trials, record NCT07484113. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07484113
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD
- NCT number
- NCT07484113
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Stanford University
- Conditions
- cGVHD
- Interventions
- Belumosudil, Sarilumab
- First posted
- 2026-03-19
- Last updated
- 2026-08-12
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events | From first dose through 6 months after treatment initiation | To evaluate the safety and tolerability of sarilumab monotherapy for the treatment of cGVHD after inadequate response to Belumosudil. |
| Secondary | Maximum Plasma Concentration (Cmax) of Sarilumab | Baseline through 6 months | Maximum observed plasma concentration of sarilumab following administration. |
| Secondary | Time to Maximum Plasma Concentration (Tmax) of Sarilumab | Baseline through 6 months | Time required to reach maximum plasma concentration following sarilumab administration. |
| Secondary | Area Under the Plasma Concentration-Time Curve (AUC) of Sarilumab | Baseline through 6 months | Area under the plasma concentration-time curve used to characterize sarilumab exposure. |
| Secondary | Incidence of serious infections | From first dose through 6 months | To evaluate the incidence of serious infections associated with sarilumab monotherapy as a rescue in subjects with belumosudil refractory cGVHD. |
| Secondary | Overall response rate | Up to 6 months | To evaluate preliminary efficacy of sarilumab monotherapy as a rescue in subjects with cGVHD after inadequate response to belumosudil |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07484113
GET https://conductscience.org/api/trials/v1/NCT07484113/registered